Research ArticleOriginal Article
Open Access

Efficacy and safety of rituximab in patients with multiple sclerosis

An observational study at a tertiary center in Makkah, Saudi Arabia

Yassir M. Almatrafi, Mohammed A. Babakkor, Muhammed Irfan, Ebaa T. Samkari, Waleed M. Alzahrani, Doaa K. Mohorjy, Sarmad Zahoor, Muhammad T. Farooq and Hafiz M. Sajid Jehangir
Neurosciences Journal April 2022, 27 (2) 65-70; DOI: https://doi.org/10.17712/nsj.2022.2.20210122

Article Figures & Data

Figures

Tables

  • Table 1

    - Distribution of clinical and demographic variables.

    Variablesn(%)
    Gender
    Male12(38.7)
    Female19(61.3)
    MS Phenotype
    Progressive6(19.4)
    Relapsing Remitting25(80.6)
    Previous use of DMT
    Yes22(71)
    No9(29)
    No Drug9(29)
    Type of DMT used
    Fingolimod8(25.8)
    Teriflunomide7(22.6)
    Diethyl fumarate5(16.1)
    Natalizumab1(3.2)
    Activity
    MRI Activity8(25.8)
    Clinical Relapse4(12.9)
    Both Relapse and Activity10(32.3)
    Indication of Rituximab
    Aggressive Disease3(9.7)
    Side Effects of the Medicine4(12.9)
    Patient Preference2(6.5)

    DMT: Disease Modifying therapy, MS: Multiple sclerosis, MRI: Magnetic resonance imaging

    • Table 2

      - Efficacy data of rituximab after one-year follow-up

      VariablesBefore treatmentAfter treatmentP-value
      Mean±SD
      Clinical Relapse1.67±0.970.06±0.25<0.001
      MRI Activity1.84±1.031.03±0.18<0.001
      EDSS Score3.16±2.142.80±2.280.141

      EDSS - Expanded Disability Status Scale, MRI - Magnetic Resonance Imaging

      Back to top

      In this issue

      Print
      Download PDF
      Email Article
      Citation Tools
      Bookmark this article

      Jump to section